International Trade Today is a service of Warren Communications News.
Subscriber Login
FDA
to
Refine Category Search
Clear Terms

Search Primer

Multi-word term: Place inside quotes to ensure an exact match together (e.g. "China import").

Term list: Separate terms with spaces, not commas or semicolons to find either word (e.g. AD/CVD antidumping).

Acronyms: Use all capital letters (e.g., ACE).

Required term: If a term must be included in any resulting articles, prefix it with a plus sign (e.g., CBP +releases).

Excluded term: If a term should be excluded from any articles being found, prefix it with a minus sign (e.g., -ruling).

Singular form: Use the singular form when doing multi-word terms (e.g. "russian export control" instead of "russian export controls").

Shortest word form: When you have different word forms in a quoted term, include the shortest version if it is the last part of the expression (e.g., "entity list" instead of "entity listing" or "entity listed").

FDA Debars Importer for Honey Smuggling
July 7, 2015 |FDA

The Food and Drug Administration on July 7 issued an order debarring Chung Po Liu from importing food for a period of five years due to his conviction for honey smuggling (here). According to FDA, Liu pleaded guilty in 2010 to misrepresenting the country of origin of honey he imported from China so as to avoid paying antidumping duties. Liu also admitted that he had introduced honey that contained the unsafe food additive ciprofloxacin, an antibiotic, said FDA.

FDA to Step Up Enforcement on Unapproved Ear Drops for Treatment of Ear Infections
July 2, 2015 |FDA

The Food and Drug Administration on July 2 announced its intent to step up enforcement on unapproved ear drops labeled for treatment of ear infections and inflammation (here). The agency says unapproved and misbranded single-ingredient otic drug products containing benzocaine; fixed-dose combination otic drug products containing benzocaine and antipyrine; fixed-dose combination otic drug products containing benzocaine, antipyrine, and zinc acetate; fixed-dose combination otic drug products containing benzocaine, chloroxylenol, and hydrocortisone; fixed-dose combination otic drug products containing chloroxylenol and fixed-dose combination otic drug products containing chloroxylenol, pramoxine, and hydrocortisone are being marketed without evidence of safety or effectiveness, and have resulted in several cases of allergic reactions. FDA “intends to take enforcement action against such products and those who manufacture them or cause them to be manufactured or shipped in interstate commerce,” it said.

FDA Issues Draft Guidance on UDI Labeling for Medical Devices
June 29, 2015 by Brian Feito|FDA

The Food and Drug Administration issued a guidance document on its unique device identifier (UDI) system for medical devices (here). The guidance contains information on effective dates, label contents, and which products are subject to the new requirements. The UDI system will begin taking effect Sept. 24 for Class III devices.